Wiener klinische Wochenschrift
-
Wien. Klin. Wochenschr. · Jul 2024
Eeny, meeny, miny, moe-Summer time and out are you? The working population in the EU would likely benefit from elimination of daylight saving time.
Daylight (saving) time (DST) is an over one century old practice to maximize the overlap between natural day light and individual active time (i.e., non-sleep time). Whether to abandon the practice is subject to an ongoing, twice a year intensifying debate. A request to abandon the practice is based on the lack of benefits in terms of energy savings and potential negative health effects. ⋯ Based on publicly available data we incorporated an approximation of the 27 European Union (EU) countries' spatial population distribution into a calculation of average exposure to morning sunlight under DST or no DST conditions for each EU27 country and the entire region. An online app offers visualization of these differences on the country level alongside a population-weighted average for the EU27. Our findings support that the majority of the EU's working population would likely benefit from the elimination of daylight saving time if maximizing an adequate morning stimulus is the primary goal and adjusting actual time zones or biennially changing the clock is not an option.
-
This guideline is intended to provide practical guidance for the diagnosis and treatment of haemophilia in Austria. Few randomized controlled interventional trials are available addressing the treatment of haemophilia, therefore recommendations are usually based on low level of evidence and represent expert consensus. ⋯ It includes recommendations and suggestions for diagnosis and follow-up visits and pharmacological therapies for treatment and prophylaxis. Further topics comprise special aspects in children and adults with severe haemophilia, outcome measurement, and management of trauma, special bleedings and interventions, including dental procedures, inhibitors, management of haemophilia carriers, and psychosocial aspects.
-
Wien. Klin. Wochenschr. · Jul 2024
Editorial Case ReportsSummertime, wintertime, a biannual shift or what? : A polylemma!
-
Wien. Klin. Wochenschr. · Jul 2024
Multicenter StudyProspective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Since 1979 Austrian children and adolescents with acute lymphoblastic leukemia (ALL) have been treated according to protocols of the Berlin-Frankfurt-Münster (BFM) study group. The Associazione Italiana di Ematologia e Oncologia Pediatrica and BFM (AIEOP-BFM) ALL 2000 study was designed to prospectively study patient stratification into three risk groups using minimal residual disease (MRD) on two time points during the patient's early disease course. The MRD levels were monitored by detection of clone-specific rearrangements of the immunoglobulin and T‑cell receptor genes applying a quantitative polymerase chain reaction-based technique. ⋯ Event-free survival for patients with precursor B‑cell and T‑cell ALL were 84 ± 2% (n = 521) and 84 ± 4% (n = 87; p = 0.460), respectively. The MRD assessment was feasible in 94% of the patients and allowed the definition of precursor B‑cell ALL patients with a low, intermediate or high risk of relapse even on top of clinically relevant subgroups. A similar finding with respect to MRD relevance in T‑ALL patients was not possible due to the small number of patients and events. Since this pivotal international AIEOP-BFM ALL 2000 trial, molecular response to treatment has been continuously used with additional refinements to stratify patients into different risk groups in all successive trials of the AIEOP-BFM ALL study group.